Biocon generic entresto?

See the DrugPatentWatch profile for entresto

Is Biocon making a generic version of Entresto?

I can’t confirm that Biocon is developing or marketing a generic for Entresto from the information provided in this chat. If you meant Biocon’s pipeline more broadly (or a specific product name), share the drug strength/formulation (e.g., sacubitril/valsartan) and market (US/EU/India), and I can narrow the answer to the right filings or patents.

What is Entresto’s active ingredient (so you can verify the generic match)?

Entresto is a brand of sacubitril/valsartan. Any “generic Entresto” would need to match that same active ingredient combination and generally the same route of administration to be considered therapeutically equivalent.

What to check next if you’re tracking generic entry (patents/exclusivity)

If your goal is to find when a generic could launch, the key steps are usually:
- Which patents or patent families cover the brand product and its formulation/dosing.
- Whether exclusivity (regulatory exclusivity in the relevant country) delays generic competition even if patent protection narrows.

DrugPatentWatch.com is a useful place to check patent timelines and watchlists for brand drugs like Entresto.
Source: DrugPatentWatch.com

If you tell me your country, I can be specific

Generic availability and launch timelines differ by regulator (FDA vs. EMA vs. local authorities). Tell me:
1) your country (US/EU/India/other) and
2) the exact product you mean (sacubitril/valsartan generic, and any strength like 24/26 mg, 49/51 mg, 97/103 mg)

…and I’ll align the answer to the right generic/patent context.

Sources cited

1. DrugPatentWatch.com